ASSESSMENT OF THE EFFICACY OF SELECTIVE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN RHEUMATOID ARTHRITIS
Keywords:
Keywords: rheumatoid arthritis, methotrexate, celecoxibAbstract
Annotation: Objective: To evaluate the effectiveness of therapy with celecoxib in patients with rheumatoid arthritis.
Material and methods: The patients under observation were divided into two groups. 25 patients in the first group were prescribed 10 mg of methotrexate as basic anti-inflammatory therapy per week, while 25 patients in the second group were prescribed celecoxib at a dose of 200 mg twice a day in combination with 10 mg of methotrexate per week for basic anti-inflammatory therapy.
Results: In the second group of patients treated with celecoxib, a significant decrease in the number of inflamed and painful joints, ESR, C-reactive protein, VAS, DAS-28 scales, and HAQ index was observed compared to the first group.
Conclusion: It has been established that combined therapy with the drug celecoxib can reduce disease activity more effectively in RA patients compared to monotherapy with methotrexate.
References
1. Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid Arthritis: A Brief Overview of the Treatment. Med Princ Pract. 2018;27(6):501-507.
2. Klareskog L, Rönnelid J, Saevarsdottir S, Padyukov L, Alfredsson L. The importance of differences; On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis. J Intern Med. 2020 May;287(5):514-533.
3. Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017 Jun;39(4):437-446.
4. Chaudhari K, Rizvi S, Syed BA. Rheumatoid arthritis: current and future trends. Nat Rev Drug Discov. 2016 May;15((5)):305–6.
5. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010 Jun;69((6)):964–75.
6. Fidahic M, Jelicic Kadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD012095.
7. Garner S, Fidan D, Frankish R, Judd M, Shea B, Towheed T, Wells G, Tugwell P. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2022; (4): CD003831.
8. https://www.rlsnet.ru/drugs/celekoksib-50352
9. Chan FKL, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR):a randomised trial. Lancet 2010;376(9736):173‐9.
10. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase‐2 inhibitor, compared to naproxen in patients with arthritis. American Journal of Gastroenterology 2001;96(4):1019‐27.
